Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionactin binding

EZR EPS8 XIRP1 DST MYH13 MAP2 PSG9 MYO1H RDX MYO1B MSN

1.72e-054799511GO:0003779
GeneOntologyMolecularFunctioncytoskeletal protein binding

EZR TTBK2 EPS8 XIRP1 DST MYH13 BRCA1 MAP2 MAP4 PSG9 MYO1H RDX MYO1B CCDC88B MSN

2.05e-0410999515GO:0008092
GeneOntologyMolecularFunctioncytoskeletal motor activity

MYH13 DYNC2H1 MYO1H MYO1B DNAH14

2.51e-04118955GO:0003774
GeneOntologyMolecularFunctiondynein light intermediate chain binding

DYNC2H1 CCDC88B DNAH14

3.14e-0428953GO:0051959
GeneOntologyBiologicalProcesspositive regulation of early endosome to late endosome transport

EZR RDX MSN

8.04e-069963GO:2000643
GeneOntologyBiologicalProcessregulation of protein localization to early endosome

EZR RDX MSN

1.15e-0510963GO:1902965
GeneOntologyBiologicalProcesspositive regulation of protein localization to early endosome

EZR RDX MSN

1.15e-0510963GO:1902966
GeneOntologyBiologicalProcessnegative regulation of microtubule binding

TTBK2 MAP2

2.14e-052962GO:1904527
GeneOntologyBiologicalProcessestablishment or maintenance of cell polarity

EZR FLOT2 DST MAP2 MAP4 SIPA1L3 TEK MSN

2.68e-05257968GO:0007163
GeneOntologyBiologicalProcesspositive regulation of protein localization to endosome

EZR RDX MSN

3.43e-0514963GO:1905668
GeneOntologyBiologicalProcessregulation of protein localization to endosome

EZR RDX MSN

4.27e-0515963GO:1905666
GeneOntologyBiologicalProcessprotein localization to early endosome

EZR RDX MSN

5.24e-0516963GO:1902946
GeneOntologyBiologicalProcessregulation of early endosome to late endosome transport

EZR RDX MSN

1.05e-0420963GO:2000641
GeneOntologyBiologicalProcesspositive regulation of intracellular transport

EZR BRCA1 MAP2 RDX TEK MSN

1.11e-04162966GO:0032388
GeneOntologyBiologicalProcessestablishment of cell polarity

EZR FLOT2 MAP2 MAP4 SIPA1L3 MSN

1.80e-04177966GO:0030010
GeneOntologyCellularComponentmicrovillus

EZR MYO1H NFASC RDX MYO1B TEK MSN

1.48e-06123957GO:0005902
GeneOntologyCellularComponentactin-based cell projection

EZR EPS8 MAP2 MYO1H NFASC RDX MYO1B TEK MSN

4.95e-06278959GO:0098858
GeneOntologyCellularComponentactin cytoskeleton

EZR FLOT2 XIRP1 DST MYH13 MAP2 MYO1H ITSN1 SIPA1L3 RDX MYO1B TEK

1.16e-055769512GO:0015629
GeneOntologyCellularComponentcell-cell junction

EZR FLOT2 XIRP1 DST PSG9 SIPA1L3 PVR NFASC RDX FLRT1 TEK MSN

1.50e-055919512GO:0005911
GeneOntologyCellularComponentfocal adhesion

EZR FLOT2 XIRP1 DST PVR NFASC RDX FLRT1 TEK MSN

2.65e-054319510GO:0005925
GeneOntologyCellularComponenturopod

EZR FLOT2 MSN

3.19e-0514953GO:0001931
GeneOntologyCellularComponentcell-substrate junction

EZR FLOT2 XIRP1 DST PVR NFASC RDX FLRT1 TEK MSN

3.35e-054439510GO:0030055
GeneOntologyCellularComponentcell trailing edge

EZR FLOT2 MSN

3.98e-0515953GO:0031254
GeneOntologyCellularComponentadherens junction

EZR FLOT2 XIRP1 PSG9 PVR RDX MSN

5.19e-05212957GO:0005912
GeneOntologyCellularComponentcell tip

EZR RDX MSN

5.90e-0517953GO:0051286
GeneOntologyCellularComponentSchwann cell microvillus

EZR NFASC

6.11e-053952GO:0097454
GeneOntologyCellularComponentcell pole

EZR RDX MSN

9.80e-0520953GO:0060187
GeneOntologyCellularComponentfilopodium

EZR MAP2 RDX MYO1B MSN

2.47e-04123955GO:0030175
GeneOntologyCellularComponentapical part of cell

EZR FLOT2 DYNC2H1 PSG9 SIPA1L3 RDX SI MYO1B TEK MSN

3.58e-045929510GO:0045177
GeneOntologyCellularComponentcluster of actin-based cell projections

EZR EPS8 PIK3CB RDX SI MYO1B

5.44e-04223956GO:0098862
GeneOntologyCellularComponentbrush border

EZR EPS8 PIK3CB SI MYO1B

6.52e-04152955GO:0005903
GeneOntologyCellularComponentcontractile actin filament bundle

XIRP1 DST SIPA1L3 TEK

1.44e-03107954GO:0097517
GeneOntologyCellularComponentstress fiber

XIRP1 DST SIPA1L3 TEK

1.44e-03107954GO:0001725
GeneOntologyCellularComponentanchoring junction

EZR FLOT2 XIRP1 DST PSG9 SIPA1L3 PVR NFASC RDX FLRT1 TEK MSN

1.54e-039769512GO:0070161
GeneOntologyCellularComponentapical plasma membrane

EZR FLOT2 PSG9 SIPA1L3 RDX SI TEK MSN

1.69e-03487958GO:0016324
GeneOntologyCellularComponentsarcolemma

EZR DST SGCG RDX MSN

1.76e-03190955GO:0042383
GeneOntologyCellularComponentcell leading edge

EZR EPS8 FLOT2 DST DPP9 MAP2 ITSN1 RDX

2.00e-03500958GO:0031252
GeneOntologyCellularComponentactomyosin

XIRP1 DST SIPA1L3 TEK

2.01e-03117954GO:0042641
GeneOntologyCellularComponentactin filament bundle

XIRP1 DST SIPA1L3 TEK

2.07e-03118954GO:0032432
GeneOntologyCellularComponentmyosin complex

MYH13 MYO1H MYO1B

2.46e-0359953GO:0016459
GeneOntologyCellularComponentlateral element

BRCA1 SMC1B

3.32e-0319952GO:0000800
DomainERM_C_dom

EZR RDX MSN

4.92e-074943IPR011259
DomainERM

EZR RDX MSN

4.92e-074943PF00769
DomainERM

EZR RDX MSN

4.92e-074943IPR011174
DomainMoesin_tail

EZR RDX MSN

4.26e-067943IPR008954
DomainTAU_MAP_2

MAP2 MAP4

7.49e-053942PS51491
DomainTubulin-binding

MAP2 MAP4

7.49e-053942PF00418
DomainMAP_tubulin-bd_rpt

MAP2 MAP4

7.49e-053942IPR001084
DomainTAU_MAP_1

MAP2 MAP4

7.49e-053942PS00229
DomainMAP2/MAP4/Tau

MAP2 MAP4

7.49e-053942IPR027324
DomainEz/rad/moesin-like

EZR RDX MSN

1.54e-0421943IPR000798
DomainFERM_CS

EZR RDX MSN

2.31e-0424943IPR019747
DomainFERM_C

EZR RDX MSN

2.95e-0426943PF09380
DomainFERM_PH-like_C

EZR RDX MSN

3.31e-0427943IPR018980
DomainFERM_C

EZR RDX MSN

3.31e-0427943SM01196
Domain-

DPP9 DPP8

3.71e-0469422.140.10.30
DomainDPPIV_N

DPP9 DPP8

3.71e-046942PF00930
DomainPeptidase_S9B_N

DPP9 DPP8

3.71e-046942IPR002469
DomainFERM_N

EZR RDX MSN

6.04e-0433943IPR018979
DomainFERM_N

EZR RDX MSN

6.04e-0433943PF09379
DomainPeptidase_S9

DPP9 DPP8

1.34e-0311942PF00326
DomainPeptidase_S9

DPP9 DPP8

1.34e-0311942IPR001375
DomainFERM_M

EZR RDX MSN

1.60e-0346943PF00373
Domain-

EZR RDX MSN

1.92e-03499431.20.80.10
DomainFERM_central

EZR RDX MSN

1.92e-0349943IPR019748
DomainFERM_domain

EZR RDX MSN

1.92e-0349943IPR000299
DomainFERM/acyl-CoA-bd_prot_3-hlx

EZR RDX MSN

2.04e-0350943IPR014352
DomainFERM_1

EZR RDX MSN

2.04e-0350943PS00660
DomainFERM_2

EZR RDX MSN

2.04e-0350943PS00661
DomainFERM_3

EZR RDX MSN

2.04e-0350943PS50057
DomainBand_41_domain

EZR RDX MSN

2.04e-0350943IPR019749
DomainB41

EZR RDX MSN

2.04e-0350943SM00295
DomainDynein_heavy_chain_D4_dom

DYNC2H1 DNAH14

2.19e-0314942IPR024317
DomainDynein_HC_stalk

DYNC2H1 DNAH14

2.19e-0314942IPR024743
DomainMT

DYNC2H1 DNAH14

2.19e-0314942PF12777
DomainAAA_8

DYNC2H1 DNAH14

2.19e-0314942PF12780
DomainDHC_fam

DYNC2H1 DNAH14

2.52e-0315942IPR026983
DomainDynein_heavy

DYNC2H1 DNAH14

2.52e-0315942PF03028
DomainDynein_heavy_dom

DYNC2H1 DNAH14

2.52e-0315942IPR004273
DomainPH_dom-like

EZR EPS8 RANBP3 ITSN1 RDX MYO1B MSN

5.71e-03426947IPR011993
PathwayWP_PTDINS45P2_IN_CYTOKINESIS_PATHWAY

EZR RDX MSN

2.50e-0512703M45558
Pubmed

A novel role for BRCA1 in regulating breast cancer cell spreading and motility.

EZR BRCA1 RDX MSN

2.72e-10596421282464
Pubmed

The ezrin-like family of tyrosine kinase substrates: receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation.

EZR RDX MSN

2.04e-0839638479753
Pubmed

Characterization of lens fiber cell triton insoluble fraction reveals ERM (ezrin, radixin, moesin) proteins as major cytoskeletal-associated proteins.

EZR RDX MSN

2.04e-08396318261459
Pubmed

Ezrin, radixin, and moesin are phosphorylated in response to 2-methoxyestradiol and modulate endothelial hyperpermeability.

EZR RDX MSN

2.04e-08396321659656
Pubmed

Expression, localization, and binding activity of the ezrin/radixin/moesin proteins in the mouse testis.

EZR RDX MSN

2.04e-08396319064715
Pubmed

Differential involvement of ezrin/radixin/moesin proteins in sphingosine 1-phosphate-induced human pulmonary endothelial cell barrier enhancement.

EZR RDX MSN

2.04e-08396321864676
Pubmed

Differential expression of ezrin/radixin/moesin (ERM) and ERM-associated adhesion molecules in the blastocyst and uterus suggests their functions during implantation.

EZR RDX MSN

2.04e-08396314613898
Pubmed

Inhibition of cell adhesion by phosphorylated Ezrin/Radixin/Moesin.

EZR RDX MSN

2.04e-08396326555866
Pubmed

Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection.

EZR RDX MSN

2.04e-08396323703860
Pubmed

Pseudomonas aeruginosa ExoS ADP-ribosyltransferase inhibits ERM phosphorylation.

EZR RDX MSN

2.04e-08396316889625
Pubmed

Effect of knockdown of ezrin, radixin, and moesin on P-glycoprotein function in HepG2 cells.

EZR RDX MSN

2.04e-08396321837648
Pubmed

Ezrin and moesin function together to promote T cell activation.

EZR RDX MSN

2.04e-08396319124745
Pubmed

Activation of Ras requires the ERM-dependent link of actin to the plasma membrane.

EZR RDX MSN

2.04e-08396322132106
Pubmed

Ezrin-radixin-moesin family proteins are involved in parvovirus replication and spreading.

EZR RDX MSN

2.04e-08396319321616
Pubmed

Deciphering brain-specific transcriptomic expression of Ezr, Rad and Msn genes in the development of Mus musculus.

EZR RDX MSN

2.04e-08396329906485
Pubmed

Activation of PKC induces leukocyte adhesion by the dephosphorylation of ERM.

EZR RDX MSN

2.04e-08396331843195
Pubmed

Increased phosphorylation of ezrin/radixin/moesin proteins contributes to proliferation of rheumatoid fibroblast-like synoviocytes.

EZR RDX MSN

2.04e-08396321278069
Pubmed

Nuclear ERM (ezrin, radixin, moesin) proteins: regulation by cell density and nuclear import.

EZR RDX MSN

2.04e-08396315149851
Pubmed

ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells.

EZR RDX MSN

2.04e-08396321352885
Pubmed

A gene family consisting of ezrin, radixin and moesin. Its specific localization at actin filament/plasma membrane association sites.

EZR RDX MSN

2.04e-0839631429901
Pubmed

ERM Proteins at the Crossroad of Leukocyte Polarization, Migration and Intercellular Adhesion.

EZR RDX MSN

2.04e-08396332098334
Pubmed

Ezrin, Radixin, and Moesin (ERM) proteins function as pleiotropic regulators of human immunodeficiency virus type 1 infection.

EZR RDX MSN

2.04e-08396318295815
Pubmed

Dmoesin controls actin-based cell shape and polarity during Drosophila melanogaster oogenesis.

EZR RDX MSN

2.04e-08396312360288
Pubmed

Dynamics and function of ERM proteins during cytokinesis in human cells.

EZR RDX MSN

2.04e-08396328889652
Pubmed

Control of adipogenesis by ezrin, radixin and moesin-dependent biomechanics remodeling.

EZR RDX MSN

2.04e-08396323116763
Pubmed

Induction of ezrin-radixin-moesin molecules after cryogenic traumatic brain injury of the mouse cortex.

EZR RDX MSN

2.04e-08396321451358
Pubmed

Differential effects of ceramide and sphingosine 1-phosphate on ERM phosphorylation: probing sphingolipid signaling at the outer plasma membrane.

EZR RDX MSN

2.04e-08396320679347
Pubmed

Differential expression and distribution of ezrin, radixin and moesin in human natural killer cells.

EZR RDX MSN

2.04e-08396312385025
Pubmed

Are ERM (ezrin/radixin/moesin) proteins targets for autoantibodies in demyelinating neuropathies?

EZR RDX MSN

2.04e-08396325286001
Pubmed

Osmotic cell shrinkage activates ezrin/radixin/moesin (ERM) proteins: activation mechanisms and physiological implications.

EZR RDX MSN

2.04e-08396317977945
Pubmed

Ezrin/radixin/moesin proteins are high affinity targets for ADP-ribosylation by Pseudomonas aeruginosa ExoS.

EZR RDX MSN

2.04e-08396315252013
Pubmed

ERM-Dependent Assembly of T Cell Receptor Signaling and Co-stimulatory Molecules on Microvilli prior to Activation.

EZR RDX MSN

2.04e-08396332160548
Pubmed

The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications.

EZR RDX MSN

2.04e-08396312734202
Pubmed

Alpha6beta4 integrin and dystroglycan cooperate to stabilize the myelin sheath.

EZR NFASC RDX MSN

2.65e-081296418579745
Pubmed

CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins.

EZR RDX MSN

8.14e-08496327793041
Pubmed

The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival.

EZR RDX MSN

8.14e-08496315096511
Pubmed

Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus.

EZR RDX MSN

8.14e-08496317237445
Pubmed

Mutagenesis of the ezrin-radixin-moesin binding domain of L-selectin tail affects shedding, microvillar positioning, and leukocyte tethering.

EZR RDX MSN

8.14e-08496315178693
Pubmed

Cortical mechanics and meiosis II completion in mammalian oocytes are mediated by myosin-II and Ezrin-Radixin-Moesin (ERM) proteins.

EZR RDX MSN

8.14e-08496320660156
Pubmed

In Vitro and in Vivo Characterization of Molecular Interactions between Calmodulin, Ezrin/Radixin/Moesin, and L-selectin.

EZR RDX MSN

8.14e-08496319129194
Pubmed

Two Sides of the Coin: Ezrin/Radixin/Moesin and Merlin Control Membrane Structure and Contact Inhibition.

EZR RDX MSN

8.14e-08496331018575
Pubmed

Ezrin is a component of the HIV-1 virological presynapse and contributes to the inhibition of cell-cell fusion.

EZR RDX MSN

8.14e-08496324760896
Pubmed

Spatial regulation of cyclic AMP-Epac1 signaling in cell adhesion by ERM proteins.

EZR RDX MSN

8.14e-08496320855527
Pubmed

Functional binding interaction identified between the axonal CAM L1 and members of the ERM family.

EZR RDX MSN

8.14e-08496312070130
Pubmed

Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.

EZR RDX MSN

8.14e-08496319890007
Pubmed

The lipid 5-phoshatase SHIP2 controls renal brush border ultrastructure and function by regulating the activation of ERM proteins.

EZR RDX MSN

8.14e-08496328302370
Pubmed

Anoctamin 1 (Tmem16A) Ca2+-activated chloride channel stoichiometrically interacts with an ezrin-radixin-moesin network.

EZR RDX MSN

8.14e-08496322685202
Pubmed

CD43 interaction with ezrin-radixin-moesin (ERM) proteins regulates T-cell trafficking and CD43 phosphorylation.

EZR RDX MSN

8.14e-08496321289089
Pubmed

The ERM proteins interact with the HOPS complex to regulate the maturation of endosomes.

EZR RDX MSN

8.14e-08496321148287
Pubmed

Rho-ROCK-dependent ezrin-radixin-moesin phosphorylation regulates Fas-mediated apoptosis in Jurkat cells.

EZR RDX MSN

8.14e-08496318941185
Pubmed

Human immunodeficiency virus (HIV)-1 proteins and cytoskeleton: partners in viral life and host cell death.

EZR RDX MSN

8.14e-08496315818415
Pubmed

Proteomic profiling in pancreatic cancer with and without lymph node metastasis.

EZR RDX MSN

8.14e-08496319152423
Pubmed

LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation.

EZR RDX MSN

8.14e-08496319255442
Pubmed

Normal development of mice and unimpaired cell adhesion/cell motility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout.

EZR RDX MSN

8.14e-0849639890997
Pubmed

Sensitivity of CYP1A1 mRNA inducibility by dioxin is the same in Cyp1a2(+/+) wild-type and Cyp1a2(-/-) null mutant mice.

EZR RDX MSN

2.03e-0759639464455
Pubmed

Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25.

EZR RDX MSN

2.03e-07596323326330
Pubmed

Regulation of NK cell trafficking by CD81.

EZR RDX MSN

2.03e-07596319830727
Pubmed

A Pak1-PP2A-ERM signaling axis mediates F-actin rearrangement and degranulation in mast cells.

EZR RDX MSN

2.03e-07596323063725
Pubmed

Interplay between RAGE, CD44, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells.

EZR RDX MSN

2.03e-07596321278261
Pubmed

Ezrin/radixin/moesin are required for the purinergic P2X7 receptor (P2X7R)-dependent processing of the amyloid precursor protein.

EZR RDX MSN

2.03e-07596322891241
Pubmed

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

EZR RDX MSN

2.03e-07596310806479
Pubmed

Vitronectin induces phosphorylation of ezrin/radixin/moesin actin-binding proteins through binding to its novel neuronal receptor telencephalin.

EZR RDX MSN

2.03e-07596323019340
Pubmed

Anchoring of protein kinase A by ERM (ezrin-radixin-moesin) proteins is required for proper netrin signaling through DCC (deleted in colorectal cancer).

EZR RDX MSN

2.03e-07596325575591
Pubmed

Gene expression in temporal lobe epilepsy is consistent with increased release of glutamate by astrocytes.

EZR RDX MSN

4.05e-07696317515952
Pubmed

Expression of ezrin in subventricular zone neural stem cells and their progeny in adult and developing mice.

EZR RDX MSN

4.05e-07696323229862
Pubmed

Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2.

EZR RDX MSN

4.05e-0769639472040
Pubmed

Human immunodeficiency virus (HIV-1) Vpr induced downregulation of NHE1 induces alteration in intracellular pH and loss of ERM complex in target cells.

EZR RDX MSN

4.05e-07696317349711
Pubmed

Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesin phosphorylation and cancer cell invasion.

EZR RDX MSN

4.05e-07696326209696
Pubmed

Adaptor protein cerebral cavernous malformation 3 (CCM3) mediates phosphorylation of the cytoskeletal proteins ezrin/radixin/moesin by mammalian Ste20-4 to protect cells from oxidative stress.

EZR RDX MSN

7.08e-07796322291017
Pubmed

MYADM controls endothelial barrier function through ERM-dependent regulation of ICAM-1 expression.

EZR RDX MSN

7.08e-07796323264465
Pubmed

PINK1 Content in Mitochondria is Regulated by ER-Associated Degradation.

EZR IGF2BP2 DST MTHFD1 ZNF804B KCTD3 RDX MYO1B NCL MSN

8.44e-07477961031300519
Pubmed

VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1- and PKCε-dependent manner.

EZR RDX MSN

1.13e-06896324788249
Pubmed

Fibril treatment changes protein interactions of tau and α-synuclein in human neurons.

KPNA5 EZR GTF2A1 DST MAP2 MAP4 RDX MYO1B NCL MSN

1.24e-06498961036634849
Pubmed

Finding the Unicorn, a New Mouse Model of Midfacial Clefting.

EZR RDX MSN

1.69e-06996331940751
Pubmed

Radixin regulates cell migration and cell-cell adhesion through Rac1.

EZR RDX MSN

1.69e-06996322467863
Pubmed

Podoplanin regulates mammary stem cell function and tumorigenesis by potentiating Wnt/β-catenin signaling.

EZR RDX MSN

4.40e-061296329361573
Pubmed

A molecular blueprint at the apical surface establishes planar asymmetry in cochlear hair cells.

EZR RDX MSN

5.71e-061396324135232
Pubmed

Embryo-uterine interaction coordinates mouse embryogenesis during implantation.

EZR RDX MSN

5.71e-061396337522872
Pubmed

Precise Somatotopic Thalamocortical Axon Guidance Depends on LPA-Mediated PRG-2/Radixin Signaling.

EZR RDX MSN

7.26e-061496327641493
Pubmed

Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism.

DPP9 DPP8

7.54e-06296223519473
Pubmed

Profibrotic mechanisms of DPP8 and DPP9 highly expressed in the proximal renal tubule epithelial cells.

DPP9 DPP8

7.54e-06296233932609
Pubmed

Expression of ezrin and moesin related to invasion, metastasis and prognosis of laryngeal squamous cell carcinoma.

EZR MSN

7.54e-06296225299115
Pubmed

Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation.

DPP9 DPP8

7.54e-06296226242871
Pubmed

Ezrin and moesin expression within the developing human cerebrum and tuberous sclerosis-associated cortical tubers.

EZR MSN

7.54e-06296212111362
Pubmed

Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines.

DPP9 DPP8

7.54e-06296222736146
Pubmed

Perspectives for Ezrin and Radixin in Astrocytes: Kinases, Functions and Pathology.

EZR RDX

7.54e-06296231382374
Pubmed

Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.

EZR MSN

7.54e-06296228624994
Pubmed

Immunohistochemical assessment of ezrin and moesin in colorectal carcinoma.

EZR MSN

7.54e-06296227042764
Pubmed

Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family.

DPP9 DPP8

7.54e-06296212534281
Pubmed

E2F6 negatively regulates BRCA1 in human cancer cells without methylation of histone H3 on lysine 9.

BRCA1 E2F6

7.54e-06296212909625
Pubmed

Moesin: a member of the protein 4.1-talin-ezrin family of proteins.

EZR MSN

7.54e-0629621924289
Pubmed

Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

DPP9 DPP8

7.54e-06296221711053
Pubmed

Specific binding of HIV-1 envelope protein gp120 to the structural membrane proteins ezrin and moesin.

EZR MSN

7.54e-0629629213396
Pubmed

BRCA1 protein and nucleolin colocalize in breast carcinoma tissue and cancer cell lines.

BRCA1 NCL

7.54e-06296220075200
Pubmed

Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site.

EZR MSN

7.54e-0629627579708
Pubmed

DPP8/9 inhibition attenuates the TGF-β1-induced excessive deposition of extracellular matrix (ECM) in human mesangial cells via Smad and Akt signaling pathways.

DPP9 DPP8

7.54e-06296238458339
Pubmed

Ezrin has properties to self-associate at the plasma membrane.

EZR MSN

7.54e-0629627844168
Pubmed

Interphase and monoastral-mitotic phenotypes of overexpressed MAP4 are modulated by free tubulin concentrations.

MAP2 MAP4

7.54e-06296212890753
Pubmed

DP8 and DP9 have extra-enzymatic roles in cell adhesion, migration and apoptosis.

DPP9 DPP8

7.54e-06296216700509
Pubmed

Emerging role for ERM proteins in cell adhesion and migration.

EZR RDX

7.54e-06296221343695
InteractionRDX interactions

CCNF EZR GTF2A1 FLOT2 DST BRCA1 RDX MYO1B DDX20 NCL MSN

1.10e-072849611int:RDX
InteractionMAPRE3 interactions

TTBK2 DST MAP2 MAP4 SIPA1L3 ZC2HC1C NCKAP5 DDX20

1.43e-05230968int:MAPRE3
Cytoband15q15.2

TTBK2 TGM5

5.09e-041696215q15.2
CytobandEnsembl 112 genes in cytogenetic band chr11q22

DYNC2H1 RDX MMP7

1.50e-03107963chr11q22
Cytoband19p13.3

DPP9 RANBP3 ACSBG2 ADGRE1

1.59e-0323796419p13.3
Cytoband5q14.1

FAM151B SPZ1

3.05e-03399625q14.1
GeneFamilyCD molecules|DASH family

DPP9 DPP8

2.98e-0476921205
GeneFamilyMyosins, class I

MYO1H MYO1B

3.96e-0486921097
GeneFamilyAnkyrin repeat domain containing|FERM domain containing

EZR RDX MSN

9.17e-04506931293
ToppCelldroplet-Bladder-nan-24m-Endothelial-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

XIRP1 MAP2 TLL1 NFASC TEK F8

3.04e-0618596690caab8d9361a541c5d5121c97c3f1cdffeeae4a
ToppCellCOPD-Lymphoid-B|Lymphoid / Disease state, Lineage and Cell class

EZR HIVEP1 SIPA1L3 LY9 PARP14 GRAMD1C

3.54e-061909661e85ee686ff6dd27c69415d524d54fa825b1daad
ToppCellASK440-Epithelial-Type_1|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq

DST MAP2 RDX MYO1B NCKAP5 PARP14

4.36e-06197966782449c522c9e16e72bf999a73090688a3aefe06
ToppCellASK428-Epithelial-Type_1|Epithelial / Donor, Lineage and Cell class of Lung cells from Dropseq

CFLAR DST MAP2 RDX MYO1B NCKAP5

4.49e-061989660047a9ef7684230ac5179efea94461480e90bdaf
ToppCellLPS_IL1RA-Endothelial-Endothelial|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST MAP4 RDX ZNF518B PARP14

4.76e-0620096672ea9882a8ed26fa1534aeb6ba0d1897dccc20c5
ToppCellLPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST RDX NCKAP5 ZNF518B TEK

4.76e-06200966dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCellLPS_IL1RA-Endothelial-Endothelial-Activated_Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

IGF2BP2 CYSLTR1 RDX MYO1B PARP14 MSN

4.76e-062009662d07237022b409c4fac6fcf99b68c8affb3007cd
ToppCellLPS_IL1RA-Endothelial|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST MAP4 RDX ZNF518B PARP14

4.76e-062009665c092b2ecc081b5d04476c56333c338cd89ab984
ToppCellLPS_anti-TNF-Endothelial-Endothelial-Activated_Gen_Cap|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 CYSLTR1 RDX NCKAP5 ZNF518B TEK

4.76e-06200966f15fffefe372005c33e31845982e2d2714ac26af
ToppCellLPS_anti-TNF-Endothelial-Endothelial-Gen_Cap|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST RDX NCKAP5 ZNF518B TEK

4.76e-06200966a2b9d1cd291d17abddc3ee2e242121412c864b8b
ToppCellLPS_IL1RA_TNF-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST RDX NCKAP5 ZNF518B TEK

4.76e-06200966b2d4e6f3e8e4da62e6b02758ab2ed8f505269f9a
ToppCellfacs-Pancreas-Exocrine-18m-Hematologic-nan|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PTPRE LY9 ADGRE1 SH2D1A CCDC88B

2.59e-0516196516f77e7a5444d2f2b210362816cd7a07b9b42af6
ToppCellfacs-Pancreas-Exocrine-18m-Hematologic|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PTPRE LY9 ADGRE1 SH2D1A CCDC88B

2.59e-05161965f5821f551cf5c64c9f75cdb723492c87aac1ece0
ToppCellfacs-Pancreas-Exocrine-18m-Hematologic-leukocyte|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PTPRE LY9 ADGRE1 SH2D1A CCDC88B

2.59e-0516196558a32a1033f379579697bda1bbf047a088e4a34f
ToppCellfacs-Lung-EPCAM-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RAB33A BRCA1 CD28 POLI SH2D1A

2.67e-05162965b877b232f0a879a9058d81ad4730e7846484b7c3
ToppCellfacs-Lung-EPCAM-3m-Lymphocytic-CD4+_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RAB33A BRCA1 CD28 POLI SH2D1A

2.67e-051629657384a4dd38ed68ca02a72df6deff4d34c9694ce1
ToppCellE18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CD28 CYSLTR1 ADGRE1 PARP14 LIX1

2.67e-05162965ec29c6f1c31e41ddcb041a49c593910edaf0532c
ToppCellPND03-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FAM151B CCNF BRCA1 CYSLTR1 ADGRE1

3.27e-05169965a1efc20e34a81ae32f8d278a5486811ade03ef24
ToppCellfacs-Large_Intestine-Proximal-3m-Epithelial-Brush_cell_of_epithelium_proper_of_large_intestine|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MAP2 MYO1B CCDC88B TMEM200C MSN

3.36e-0517096517bd7fd25a2657cb536ad47e294332920f759e95
ToppCellControl-Epithelial_cells-ECM-high_epithelial|Control / group, cell type (main and fine annotations)

DST PTPRE MAP2 MYO1B NCKAP5

3.36e-05170965e2023d66e70983c87dacbd6181d3426488d1fc57
ToppCellLeuk-UTI-Myeloid-cDC1|Leuk-UTI / Disease, Lineage and Cell Type

RAB33A DST PTPRE PIK3CB NCKAP5

3.65e-05173965226bb8d881f32d65c60f5e4c034c6d465f8e7ba5
ToppCellControl-Epithelial_cells-AT1|Control / group, cell type (main and fine annotations)

DST PTPRE MAP2 MYO1B NCKAP5

3.76e-05174965548d7f2b958a2bfd2c95eb049ceaab55a559c77d
ToppCellAT1_cells-Donor_04|World / lung cells shred on cell class, cell subclass, sample id

CFLAR DST MAP2 MYO1B NCKAP5

4.07e-051779653128b8d04687acee1ac4190b2569d6328b98eaf3
ToppCellPND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-Treg-Treg_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FAM151B CCNF BRCA1 CD28 SH2D1A

4.07e-05177965f10f77130dbb2c0ad1b436ceb4fb1deac2b0267c
ToppCell5'-Adult-Appendix-Mesenchymal-fibroblastic-Stromal_2_(NPY+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

PTPRE DYNC2H1 HGSNAT NFASC NID1

4.30e-05179965a1ea8daa0fe8900f5a04b555c77fe8ebdaa3908d
ToppCellCalu_3-infected|Calu_3 / Cell line, Condition and Strain

CFLAR PNPT1 DST CHD8 PARP14

4.77e-051839658f7f5000645f24f20a8d7700c4df1f8953a1780b
ToppCell3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-B_cell-B_cells-B_cells_L.1.5.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

EZR HIVEP1 NCL LY9 PARP14

5.03e-05185965e913c64f9b4873443d88dce270f0b7b6d1b4cbce
ToppCellAdult-Epithelial-alveolar_epithelial_cell_type_1-D175|Adult / Lineage, Cell type, age group and donor

DST MAP2 SIPA1L3 MYO1B NCKAP5

5.03e-0518596532b4e68e551d435a732f253f6ad83408c759a642
ToppCellCOVID-19-Fibroblasts-Pericytes|COVID-19 / group, cell type (main and fine annotations)

EPS8 NFASC NID1 MYO1B NCKAP5

5.03e-051859654905adaeeffd353e089578e5ea614437dbe794e6
ToppCell3'-Child04-06-SmallIntestine-Hematopoietic-Myeloid-Lymphoid_DC|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

BLVRA CFLAR HIVEP1 RDX MMP7

5.03e-0518596548de4d9fad55077732bf64eca4919103ecbc1512
ToppCellIPF-Epithelial-ATI|Epithelial / Disease state, Lineage and Cell class

PTPRE MAP2 MYO1B NCKAP5 MSN

5.16e-05186965d436ee6cabbde8553ec5e6e55022274090d9f41a
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

EPS8 MAP2 NFASC NID1 MYO1B

5.29e-05187965ec4b694487cc446999c7b27b119950a4f252c4b3
ToppCellCOPD-Stromal-Pericyte|Stromal / Disease state, Lineage and Cell class

EPS8 NID1 MYO1B NCKAP5 EMSY

5.29e-05187965406ecd1dabb3ed8d871aef159f7bd1e383434953
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

EPS8 MAP2 NFASC NID1 MYO1B

5.29e-05187965530e4e6d91b5c0d9aa4543caa2b734a1674c5788
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

EZR IGF2BP2 DST DYNC2H1 MYO1B

5.29e-05187965f124d2c699b717b7c02a1a70493f515b83dc2f4c
ToppCell15-Distal-Mesenchymal-Pericyte|Distal / Age, Tissue, Lineage and Cell class

EPS8 MAP2 NFASC MYO1B LIX1

5.43e-051889654963382e54aac06bf5047c7d725393db70667ee7
ToppCell3'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.3.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

EPS8 ST20 MYO1B AHCYL2 MMP7

5.56e-05189965e90ba6f6d7ba0698d04d84278aa035c28803733e
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

EZR IGF2BP2 DST DYNC2H1 MYO1B

5.56e-05189965e32172ad09e93f6ac6ea2b92145b2b73003f7970
ToppCellChildren_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

EZR DST MAP2 MYO1B NCKAP5

5.70e-0519096530b50d183d7649146eb1e79b47ba897355f1998a
ToppCellCOVID-19-Heart-EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type

EPS8 MAP2 NFASC MYO1B F8

5.70e-05190965a21653bfb7bafbc273f94fa7c13bfb48cf8fd562
ToppCellTCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_Mucinous-6|TCGA-Stomach / Sample_Type by Project: Shred V9

USP17L1 MTHFD1 USP17L3 NNT

5.79e-0597964489f5e12eb67b1850f1f2d7d4b229df1f4ceefe3
ToppCellNS-control-d_0-4-Lymphoid-CTL|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

RAB33A RGS9 LY9 SH2D1A MSN

5.85e-0519196527f2151da2f41015a979499f274ab1284a36189f
ToppCellLAM-Epithelial-AT1|Epithelial / Condition, Lineage and Cell class

CFLAR DST MAP2 NCKAP5 PARP14

5.85e-051919653457e15d1e9b36a78363d46b320c4ec46b40290a
ToppCellcontrol-Lymphoid-CTL|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

RAB33A RGS9 LY9 SH2D1A MSN

5.85e-051919658df23473e24cfa51c09986102ddd391ed0f0b9cc
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

EPS8 MAP2 NFASC NID1 MYO1B

5.85e-051919657b0d42a877540dbb346a76a62403e0d5d3e07fa6
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell_/_Pericyte-|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

EPS8 MAP2 NFASC NID1 MYO1B

5.85e-05191965cd854b9c426924fdc84bf7f411f6dea447143e79
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

EPS8 MAP2 NFASC NID1 MYO1B

5.99e-0519296524e2f15f5767a97eb3b389922bcfd7b13805e1ce
ToppCellhuman_hepatoblastoma-Endothelial_cells|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)

PTPRE MAP2 TEK GRAMD1C MSN

5.99e-05192965e09f609fed033a25baacaf4a07bbbae1076da366
ToppCell11.5-Distal-Mesenchymal-Pericyte|Distal / Age, Tissue, Lineage and Cell class

EPS8 MAP2 NID1 MYO1B LIX1

6.30e-0519496508701590496cf85ff790e54a81493c61177e76ff
ToppCellBronchial-NucSeq-Epithelial-Epi_alveolar-AT1|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DST PTPRE MAP2 MYO1B NCKAP5

6.45e-05195965a71ba5e4043e2d35a45a2c60a96b087e31832345
ToppCellControl-Myeloid-cDC1|Control / Disease, Lineage and Cell Type

DST PTPRE PIK3CB NCKAP5 TGM5

6.45e-0519596535b2fe0588877d30cbd5d3ae259fcfd959907429
ToppCellCOVID-19-kidney-Fibroblast-2|COVID-19 / Disease (COVID-19 only), tissue and cell type

EPS8 NFASC NID1 MYO1B ALDH1A3

6.45e-051959653d62ce1c696f47d4d7eb0c5bb0eec2c24b122bb2
ToppCellParenchymal-NucSeq-Epithelial-Epi_alveolar-AT1|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

DST PTPRE MAP2 MYO1B NCKAP5

6.77e-051979658d5097898dd01cedb04cb694cb480c931e08462c
ToppCellASK428-Epithelial-Type_1|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq

DST MAP2 RDX MYO1B NCKAP5

6.77e-051979659ae6661c307791c3f0ecd3d378e3d917565e5498
ToppCellrenal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

PTPRE MAP2 TLL1 PARP14 TEK

6.93e-05198965b027a141ab531d0f5d6a26811a53427e7b0771dd
ToppCelldistal-Epithelial-Alveolar_Epithelial_Type_2-2|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

EPS8 ST20 MYO1B AHCYL2 MMP7

6.93e-05198965de5748c2b66ecc432974cf095ecd241369579f7c
ToppCellLAM-Endothelial-VasEndo-2|Endothelial / Condition, Lineage and Cell class

CFLAR EPS8 RDX TEK F8

6.93e-0519896592bccaec01f1dbb17d5efcba30f7f800f674ca96
ToppCellTracheal-NucSeq-Stromal-Myofibroblastic-Muscle_perivascular_immune_recruiting|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

EPS8 NFASC NID1 MYO1B NCKAP5

6.93e-05198965b7e900fc0a1b3fa5e47dcc36ce6b0c3ce6bf9739
ToppCellLPS_IL1RA|World / Treatment groups by lineage, cell group, cell type

CFLAR IGF2BP2 CYSLTR1 ALDH1A3 MSN

7.27e-05200965a02fa5b3c4723a6eaa3c685588666c710478dd25
ToppCellLPS_only-Endothelial-Endothelial-Gen_Cap|LPS_only / Treatment groups by lineage, cell group, cell type

IGF2BP2 CYSLTR1 RDX NCKAP5 ZNF518B

7.27e-05200965eb94a5111ef0e903ee5be9f7efe571b4e6d5fce1
ToppCellcellseq2-Endothelial-Endothelial_Vascular-Endothelial_large_blood_vessel-SVEC|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

CYSLTR1 TLL1 RDX TEK F8

7.27e-05200965147ceed692655f4ed73b8a57b0b3224def1f3055
ToppCellLPS_only-Endothelial|LPS_only / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST CYSLTR1 RDX PARP14

7.27e-0520096581e76508c9050d533853d5fd2f3097b27613d836
ToppCellControl_saline-Endothelial-Endothelial-Gen_Cap|Control_saline / Treatment groups by lineage, cell group, cell type

DST RDX NCKAP5 ZNF518B TEK

7.27e-052009653b97920e1e6e2f09ddba2a861baa9c00c2970f4c
ToppCellControl_saline-Endothelial-Endothelial|Control_saline / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST RDX NCKAP5 ZNF518B

7.27e-05200965e77eba6172cabf85b8028638ed35299f2f079cd8
ToppCellLPS_IL1RA-Endothelial-Endothelial-Activated_Alv_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST MAP4 RDX PARP14

7.27e-0520096579e51afb57ca38aacebd0298e5e727b55c0cfff9
ToppCellNeuronal-Inhibitory-iA-iA_1(SST_PAX6)-PAX6|Neuronal / cells hierarchy compared to all cells using T-Statistic

EPS8 NID1 NCKAP5 TMEM200C LIX1

7.27e-052009658a8f9d9e5ffab3f736c4bd0a5bb616d442d137d1
ToppCellLPS_IL1RA_TNF-Endothelial-Endothelial|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 RDX ZNF518B PARP14 TEK

7.27e-05200965a1fa6bae5a688faf488d6925cd3fad725dfa916b
ToppCellLPS_anti-TNF-Endothelial|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST MAP4 RDX ZNF518B

7.27e-052009651d105eeda5a2c51f9a4654ffc79b7e2348ad593b
ToppCell3'-Adult-LargeIntestine-Endothelial-blood_vessel_EC-Mature_venous_EC|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CYSLTR1 TLL1 RDX TEK MSN

7.27e-05200965cee07d9370656e1c428a7a9e9fbd175129901374
ToppCellLPS_IL1RA_TNF-Endothelial|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 RDX ZNF518B PARP14 TEK

7.27e-05200965d01cec331be3b03cef80e9536fc531285bcf00f6
ToppCellLPS_anti-TNF-Endothelial-Endothelial|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST MAP4 RDX ZNF518B

7.27e-0520096560d2cbf41f37f1b11eddb4c9d9246c9c1fc5a5af
ToppCellControl_saline-Endothelial|Control_saline / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST RDX NCKAP5 ZNF518B

7.27e-052009653372c488a39fe812fa94e4f0564594186fea3db5
ToppCellLPS_only-Endothelial-Endothelial|LPS_only / Treatment groups by lineage, cell group, cell type

IGF2BP2 DST CYSLTR1 RDX PARP14

7.27e-052009654bb609a284d4e6066f17470a1736076aa4a1f84c
ToppCell(51)_cDC1|World / shred on Cell_type and subtype

DST PTPRE NCKAP5 TEK TGM5

7.98e-05204965a8cf4180c406674b7541917d1fc6127686ba5f8a
ToppCellCerebellum-Neuronal-Excitatory|Cerebellum / BrainAtlas - Mouse McCarroll V32

TLL1 ZNF804B SH2D1A CCDC88B

1.70e-04128964c30ba14320e9b98c9af9e4cd5a8c55380bb9ffa9
ToppCellFrontal_cortex-Endothelial-ENDOTHELIAL_STALK-Flt1_2|Frontal_cortex / BrainAtlas - Mouse McCarroll V32

GPX6 CNGB3 ALDH1A3 TEK

1.85e-04131964d5bc40cd585582856881081b7130dec3515b4ae0
ToppCellGlobus_pallidus-Macroglia-POLYDENDROCYTE-P1|Globus_pallidus / BrainAtlas - Mouse McCarroll V32

RAB33A PDILT NFASC NCKAP5

2.20e-0413796480f1a6cfb48ccfba1c3545fdcd5fcb3157272aca
ToppCellPND01-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

CCNF BRCA1 CYSLTR1 ADGRE1

2.52e-04142964be63c48794a227ea55978524c0f5935342fc455e
ToppCellLPS-antiTNF-Myeloid-Myeloid_granulocytic|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

CFLAR ADGRE1 CCDC88B SMC1B

2.59e-041439644a0f26eef935fe68a1da5d319503059a8a8682dd
ToppCellLPS-antiTNF-Myeloid-Myeloid_granulocytic-Neutrophils|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

CFLAR ADGRE1 CCDC88B SMC1B

2.59e-0414396465328a0a2f3972fac596e07933e74b2ef7cceb84
ToppCellPND07-Immune-Immune_Myeloid-DC-cDC2-cDC2_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

EPS8 PTPRE CYSLTR1 ADGRE1

2.66e-04144964f5d0d0564fcbec8a5d87119e0807b619faa77b0f
ToppCellCOVID-19_Moderate-multiplets|COVID-19_Moderate / disease group, cell group and cell class

NCKAP5 ALDH1A3 CCDC88B TGM5

2.88e-04147964baf15c773d7751bc6f64d4974a22738626f2b3ff
ToppCellPND07-Immune-Immune_Myeloid-DC-cDC2|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

EPS8 PTPRE CYSLTR1 ADGRE1

3.03e-0414996432e0be7da42d26956683b21a1e7ae6915e4c16fb
ToppCellICU-SEP-Lymphocyte-T_NK-CD8_Naive|ICU-SEP / Disease, Lineage and Cell Type

CD28 TXNRD3 SH2D1A F8

3.03e-04149964a66f3ebf6214b269b137ddd5f4d8d7fb3ef2d962
ToppCellPND14-Immune-Immune_Myeloid-DC-cDC2-cDC2_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

EPS8 PTPRE CYSLTR1 CCDC88B

3.27e-04152964b2e29fbda6b5f2d87cfc05423caf9cbf3b04ac65
ToppCellPND07-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD4_T-CD4_T_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

RAB33A CD28 LY9 SH2D1A

3.35e-041539640ad401cb70b9edfc6ae6ccba6879c6c2b6c4d296
ToppCellSubstantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Tmem132c_(SN/VTA_(SNr))--|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

CCNF SPZ1 GPX6

3.41e-0463963e1b68ef6123ad084ce602b09fd1ba394785797e5
ToppCellSubstantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Tmem132c_(SN/VTA_(SNr))|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

CCNF SPZ1 GPX6

3.41e-04639639bfd9ba1335a155ed9e56dd41dd3621b37d4234e
ToppCellSubstantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Tmem132c_(SN/VTA_(SNr))-|Substantia_nigra / BrainAtlas - Mouse McCarroll V32

CCNF SPZ1 GPX6

3.41e-04639639a90c761898618fc7e5e2984baa1021b74d4ac39
ToppCellP28-Hematopoietic|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

CD28 LY9 ADGRE1 SH2D1A

3.43e-0415496413980ae1957b05350c11171c9c118decfe998d3d
ToppCellPND07-Immune-Immune_Myeloid-DC-cDC2-cDC2_G2M|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

FAM151B EPS8 CYSLTR1 CCDC88B

3.43e-04154964e3a8a1e63ab345de62bd2e5e54342b00f04ae422
ToppCellFetal_29-31_weeks-Immune-dendritic_cell-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

PTPRE SIPA1L3 PDILT CCDC88B

3.52e-041559649f937ae48767fdcf1a944af4de0530d9c0ab441d
ToppCellfacs-MAT-Fat-24m-Myeloid-macrophage|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BLVRA PIK3CB CYSLTR1 ADGRE1

3.52e-04155964d0c1608f8f6b6f4174e51d610501c707cba5e015
ToppCellfacs-Marrow-KLS-18m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DST PIK3CB CYSLTR1 AHCYL2

3.69e-041579645d08ff0ba9d3df9cc30f13cab2d2b395ea6f3446
ToppCellP28-Hematopoietic-Immune-immune_cell_unspecified|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

CD28 LY9 ADGRE1 SH2D1A

3.69e-04157964a70f93aff07b6b7a9efce33b12b024116648dc0a
ToppCellP28-Hematopoietic-Immune|P28 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase

CD28 LY9 ADGRE1 SH2D1A

3.69e-04157964b1f520b1e0ea7abb19d0dd27021eafbea0fd90cd
ToppCell343B-Myeloid-Macrophage-SPP1+_Macrophage|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

IGF2BP2 TLL1 MMP7 F8

3.69e-041579644183dbed6b31ebe13ef33eb19ba6d0fb4f625953
ToppCellfacs-Marrow-KLS-18m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DST PIK3CB CYSLTR1 AHCYL2

3.69e-04157964ad9c9b7dfeee3ae46e7e593c51a0407df12195b4
ToppCell343B-Myeloid-Macrophage-SPP1+_Macrophage|Macrophage / Donor, Lineage, Cell class and subclass (all cells)

IGF2BP2 TLL1 MMP7 F8

3.78e-04158964de65af8d3b8514b17978155f31975e2347b75251
ToppCellmild_COVID-19_(asymptomatic)-B_intermediate|World / disease group, cell group and cell class (v2)

EZR MYO1B LY9 GRAMD1C

3.97e-041609646722934e153b72039c3c4308557d0ef879a30638
DrugCeforanide [60925-61-3]; Up 200; 7.6uM; MCF7; HT_HG-U133A

CFLAR MAP4 RANBP3 ITSN1 PVR AHCYL2 NNT

1.55e-051939475351_UP
Drug(-)-Isoproterenol hydrochloride [5984-95-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A

CFLAR TTBK2 MAP4 ATG13 SIPA1L3 PVR MYO1B

1.60e-051949476833_DN
Drug5279552; Up 200; 22uM; MCF7; HT_HG-U133A_EA

CFLAR ST20 PIK3CB ATG13 AHCYL2 VAMP4 F8

1.60e-05194947843_UP
DrugSB 202190; Down 200; 1uM; PC3; HT_HG-U133A

EZR MAP2 MAP4 PIK3CB ATG13 ZC2HC1C MAPK7

1.66e-051959477058_DN
DrugSulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A

CFLAR BRCA1 MAP4 DYNC2H1 ATG13 RANBP3 NNT

1.66e-051959473409_DN
DrugQuinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

CFLAR PTPRE MAP4 RANBP3 SIPA1L3 AHCYL2 EMSY

1.66e-051959473191_DN
DrugUAMC00132

DPP9 DPP8

1.69e-052942ctd:C524159
DrugAp 25

MAP2 MSN

1.69e-052942CID001010724
DrugMethylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; MCF7; HT_HG-U133A

CFLAR ST20 RANBP3 PVR MYO1B NNT EMSY

1.71e-051969473333_DN
DrugNomegestrol acetate [58652-20-3]; Down 200; 10.8uM; MCF7; HT_HG-U133A

CFLAR GTF2A1 MAP4 SIPA1L3 PVR CNGB3 MAPK7

1.71e-051969475461_DN
DrugLoxapine succinate [27833-64-3]; Down 200; 9uM; MCF7; HT_HG-U133A

BLVRA BRCA1 MAP4 RANBP3 ITSN1 CHD8 AHCYL2

1.71e-051969475293_DN
DrugDienestrol [84-17-3]; Down 200; 15uM; MCF7; HT_HG-U133A

CFLAR ST20 DYNC2H1 RANBP3 ITSN1 AHCYL2 NNT

1.71e-051969473448_DN
DrugApramycin [37321-09-8]; Down 200; 7.4uM; HL60; HT_HG-U133A

BLVRA ST20 MAP4 DYNC2H1 AHCYL2 VAMP4 TGM5

1.71e-051969472914_DN
DrugTerconazole [67915-31-5]; Down 200; 7.6uM; MCF7; HT_HG-U133A

TTBK2 MAP4 PVR CNGB3 AHCYL2 MAPK7 EMSY

1.71e-051969474407_DN
DrugD-cycloserine [68-41-7]; Down 200; 39.2uM; MCF7; HT_HG-U133A

CFLAR ST20 RANBP3 SIPA1L3 HGSNAT MYO1B F8

1.71e-051969476782_DN
DrugD-cycloserine [68-41-7]; Down 200; 39.2uM; HL60; HT_HG-U133A

GTF2A1 RAB33A MAP4 PVR MYO1B EMSY TGM5

1.77e-051979476139_DN
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; PC3; HT_HG-U133A

KPNA5 MED20 GTF2A1 PVR CNGB3 AHCYL2 GRAMD1C

1.77e-051979474477_DN
DrugEpitiostanol [2363-58-8]; Down 200; 13uM; MCF7; HT_HG-U133A

CFLAR ST20 MAP4 RANBP3 ITSN1 SIPA1L3 F8

1.77e-051979477342_DN
DrugMeclocycline sulfosalicylate [73816-42-9]; Down 200; 5.8uM; MCF7; HT_HG-U133A

MAP4 RANBP3 SIPA1L3 PVR CNGB3 HGSNAT EMSY

1.77e-051979473277_DN
DrugPropidium iodide [25535-16-4]; Down 200; 6uM; MCF7; HT_HG-U133A

CFLAR MAP4 SGCG PVR MAPK7 GRAMD1C EMSY

1.83e-051989476104_DN
DrugUrapidil hydrochloride [64887-14-5]; Up 200; 9.4uM; MCF7; HT_HG-U133A

BLVRA TTBK2 DYNC2H1 ITSN1 CNGB3 AHCYL2 EMSY

1.83e-051989475295_UP
Drugtopiramate; Up 200; 3uM; MCF7; HT_HG-U133A_EA

TTBK2 ST20 MAP4 PIK3CB RANBP3 SIPA1L3 AHCYL2

1.83e-05198947915_UP
DrugMeclofenoxate hydrochloride [3685-84-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A

CFLAR MAP4 RANBP3 ITSN1 PVR MYO1B NNT

1.95e-052009473405_DN
DrugAC1MHZPD

DPP9 CD28 DPP8

2.40e-0514943CID003035635
DrugSureCN3749646

DPP9 DPP8

5.05e-053942CID011530920
Drugphenyltetrazole

CYSLTR1 POLI

5.05e-053942CID000087425
DrugSureCN3745540

DPP9 DPP8

5.05e-053942CID011974437
DrugSureCN3749947

DPP9 DPP8

5.05e-053942CID011974435
DrugABT-279

DPP9 DPP8

5.05e-053942CID016049769
DrugCyanopyrrolidine 39

DPP9 DPP8

5.05e-053942CID011117606
DrugCyanopyrrolidine 38

DPP9 DPP8

5.05e-053942CID010932707
DrugSureCN3748611

DPP9 DPP8

5.05e-053942CID011974325
DrugDiprolyl-alanine

DPP9 DPP8

5.05e-053942CID000193559
DrugDMMP

DST RDX MSN

5.32e-0518943CID000012958
DrugAC1Q5JYX

DPP9 NID1 MMP7 DPP8

7.36e-0554944CID000002020
Drugglycylproline 4-nitroanilide

DPP9 DPP8

1.01e-044942ctd:C042892
DrugN-DAM

NCL F8

1.01e-044942CID000152320
DrugAp 21

MAP2 MSN

1.01e-044942CID003030080
DrugMyricetin [529-44-2]; Down 200; 12.6uM; HL60; HT_HG-U133A

CCNF BLVRA FLOT2 DYNC2H1 ITSN1 TGM5

1.38e-041909461334_DN
DrugButacaine [149-16-6]; Down 200; 13uM; MCF7; HT_HG-U133A

CFLAR FLOT2 SGCG RANBP3 CNGB3 AHCYL2

1.46e-041929463469_DN
DrugNaltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; MCF7; HT_HG-U133A

CCNF TTBK2 GTF2A1 MAP4 SGCG RANBP3

1.51e-041939462209_DN
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; HL60; HG-U133A

HIVEP1 ST20 MAP4 ATG13 KCTD3 VAMP4

1.51e-041939461412_DN
DrugAcenocoumarol [152-72-7]; Down 200; 11.4uM; MCF7; HT_HG-U133A

CFLAR GTF2A1 BRCA1 MAP4 PVR NNT

1.51e-041939467232_DN
DrugDiphenidol hydrochloride [3254-89-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A

BLVRA CFLAR MAP4 PIK3CB AHCYL2 VAMP4

1.55e-041949467406_DN
DrugFenspiride hydrochloride [5053-08-7]; Up 200; 13.4uM; HL60; HG-U133A

CFLAR RAB33A MAP4 ITSN1 SIPA1L3 CNGB3

1.55e-041949461422_UP
DrugSparteine (-) [90-39-1]; Down 200; 17uM; MCF7; HT_HG-U133A

KPNA5 ST20 PIK3CB AHCYL2 NNT EMSY

1.55e-041949464391_DN
DrugPilocarpine nitrate [148-72-1]; Up 200; 14.8uM; PC3; HT_HG-U133A

CD28 PVR ZC2HC1C SH2D1A NNT EMSY

1.55e-041949466741_UP
DrugPipenzolate bromide [125-51-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A

PTPRE RANBP3 SIPA1L3 MYO1B VAMP4 NNT

1.55e-041949463460_DN
DrugRapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A

FLOT2 MAP4 DYNC2H1 RANBP3 PVR AHCYL2

1.55e-041949466958_DN
DrugHeptaminol hydrochloride [543-15-7]; Down 200; 22uM; HL60; HT_HG-U133A

BLVRA TTBK2 MAP4 ATG13 ITSN1 SIPA1L3

1.59e-041959461866_DN
DrugPipenzolate bromide [125-51-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MAP4 RANBP3 MYO1B AHCYL2 VAMP4 EMSY

1.59e-041959466821_DN
DrugChlorpropamide [94-20-2]; Down 200; 14.4uM; MCF7; HT_HG-U133A

FLOT2 ST20 CNGB3 VAMP4 NNT EMSY

1.59e-041959463210_DN
DrugFamotidine [76824-35-6]; Up 200; 11.8uM; PC3; HG-U133A

CCNF BLVRA CFLAR RANBP3 ITSN1 SH2D1A

1.59e-041959461946_UP
DrugScopoletin [92-61-5]; Down 200; 20.8uM; MCF7; HT_HG-U133A

CFLAR ST20 BRCA1 MAP4 PVR EMSY

1.59e-041959466510_DN
DrugButylparaben [94-26-8]; Down 200; 20.6uM; MCF7; HT_HG-U133A

GTF2A1 PTPRE BRCA1 PVR MYO1B NNT

1.59e-041959465245_DN
DrugHydralazine hydrochloride [304-20-1]; Down 200; 20.4uM; MCF7; HT_HG-U133A

ST20 RANBP3 SIPA1L3 PVR AHCYL2 EMSY

1.59e-041959462311_DN
DrugEpirizole [18694-40-1]; Up 200; 17uM; PC3; HT_HG-U133A

CFLAR ITSN1 ZC2HC1C MAPK7 VAMP4 NNT

1.64e-041969461803_UP
DrugHydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; MCF7; HT_HG-U133A

FLOT2 ST20 MAP4 RANBP3 CNGB3 AHCYL2

1.64e-041969461524_DN
DrugSulindac [38194-50-2]; Down 200; 11.2uM; HL60; HT_HG-U133A

BLVRA TTBK2 ATG13 RANBP3 SIPA1L3 NNT

1.64e-041969461857_DN
Drug2-propylpentanoic acid; Up 200; 200uM; MCF7; HT_HG-U133A

KPNA5 BLVRA PTPRE MAPK7 F8 EMSY

1.64e-041969466934_UP
DrugEtilefrine hydrochloride [534-87-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A

KPNA5 CFLAR MAP4 PVR MYO1B MAPK7

1.64e-041969464415_DN
DrugRauwolscine hydrochloride [6211-32-1]; Up 200; 10.2uM; PC3; HT_HG-U133A

GTF2A1 PVR ZC2HC1C MMP7 LY9 TEK

1.64e-041969465800_UP
DrugTelenzepine dihydrochloride [147416-96-4]; Down 200; 9uM; HL60; HT_HG-U133A

TTBK2 MAP4 RANBP3 KCTD3 LY9 VAMP4

1.64e-041969462388_DN
DrugTolazoline hydrochloride [59-97-2]; Down 200; 20.4uM; MCF7; HT_HG-U133A

CFLAR GTF2A1 MAP4 PIK3CB RANBP3 NNT

1.64e-041969464844_DN
DrugLY 294002; Down 200; 10uM; HL60; HT_HG-U133A

CCNF MAP4 DYNC2H1 RANBP3 AHCYL2 TGM5

1.64e-041969462687_DN
DrugEstropipate [7280-37-7]; Down 200; 9.2uM; HL60; HT_HG-U133A

MAP4 RANBP3 SIPA1L3 VAMP4 NNT F8

1.64e-041969462506_DN
DrugThioproperazine dimesylate [2347-80-0]; Up 200; 6.2uM; MCF7; HT_HG-U133A

CFLAR RAB33A ST20 MAP2 MAP4 ADGRE1

1.64e-041969462236_UP
DrugViomycin sulfate [37883-00-4]; Down 200; 5.2uM; MCF7; HT_HG-U133A

CFLAR PIK3CB ATG13 RANBP3 PVR ACSBG2

1.64e-041969463541_DN
DrugCinnarizine [298-57-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A

RAB33A MAP2 DYNC2H1 CD28 PVR MAPK7

1.64e-041969463175_UP
Drugprodipine

DPP9 DPP8

1.67e-045942CID000065775
DrugAC1L1H6N

XIRP1 POLI

1.67e-045942CID000003999
Drugarginyl(PMC)-pyrrolidine-2-nitrile

DPP9 DPP8

1.67e-045942CID000487437
DrugHEMA-EMA

E2F6 F8

1.67e-045942CID003082253
Drug1,2-dihydropyridine

TXNRD3 POLI

1.67e-045942CID000407038
Drugalanylproline-4-nitroanilide

DPP9 DPP8

1.67e-045942ctd:C083013
DrugNeostigmine bromide [114-80-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A

MAP4 ATG13 RANBP3 ITSN1 PVR NNT

1.68e-041979465335_UP
DrugConessine [546-06-5]; Down 200; 11.2uM; MCF7; HT_HG-U133A

EZR TTBK2 FLOT2 MAP4 RANBP3 VAMP4

1.68e-041979464777_DN
DrugPempidine tartrate [546-48-5]; Down 200; 13uM; HL60; HT_HG-U133A

KPNA5 BLVRA IGF2BP2 MAP4 RANBP3 PVR

1.68e-041979462172_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A

CFLAR TTBK2 FLOT2 PTPRE MAP4 CNGB3

1.68e-041979463566_DN
DrugTiaprofenic acid [33005-95-7]; Down 200; 15.4uM; HL60; HT_HG-U133A

CCNF RAB33A DYNC2H1 RANBP3 ITSN1 ADGRE1

1.68e-041979462492_DN
DrugGallamine triethiodide [65-29-2]; Down 200; 4.4uM; PC3; HT_HG-U133A

MED20 GTF2A1 ST20 BRCA1 AHCYL2 GRAMD1C

1.68e-041979465735_DN
DrugCyclobenzaprine hydrochloride [6202-23-9]; Down 200; 12.8uM; HL60; HT_HG-U133A

MED20 CFLAR RANBP3 MYO1B VAMP4 EMSY

1.73e-041989461332_DN
DrugTetracycline hydrochloride [64-75-5]; Down 200; 8.4uM; PC3; HT_HG-U133A

BLVRA MAP4 CNGB3 NID1 MYO1B MAPK7

1.73e-041989462080_DN
DrugIsoflupredone acetate [338-98-7]; Down 200; 9.6uM; MCF7; HT_HG-U133A

CFLAR GTF2A1 MAP4 SIPA1L3 NNT EMSY

1.73e-041989465545_DN
Drugfluphenazine dihydrochloride; Up 200; 10uM; HL60; HT_HG-U133A

GTF2A1 MAP2 RANBP3 PVR CNGB3 MYO1B

1.73e-041989466196_UP
DrugAdenosine 5'-monophosphate monohydrate [18422-05-4]; Up 200; 11uM; MCF7; HT_HG-U133A

RAB33A SIPA1L3 NID1 MAPK7 NNT GRAMD1C

1.73e-041989463237_UP
DrugGabazine [105538-73-6]; Down 200; 10.8uM; HL60; HT_HG-U133A

CCNF FLOT2 DYNC2H1 ATG13 ITSN1 AHCYL2

1.73e-041989461316_DN
DrugNaftifine hydrochloride [65473-14-5]; Down 200; 12.4uM; MCF7; HT_HG-U133A

CFLAR DYNC2H1 ITSN1 PVR VAMP4 NNT

1.73e-041989467032_DN
DrugSulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; HL60; HT_HG-U133A

CFLAR EZR RAB33A MAP4 LY9 EMSY

1.73e-041989461859_UP
DrugBenzocaine [94-09-7]; Down 200; 24.2uM; MCF7; HT_HG-U133A

TTBK2 FLOT2 MAP4 RANBP3 SIPA1L3 AHCYL2

1.73e-041989464808_DN
DrugApramycin [37321-09-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A

GTF2A1 ST20 BRCA1 MAP4 AHCYL2 NNT

1.73e-041989467334_DN
DrugErgocryptine-alpha [511-09-1]; Down 200; 7uM; MCF7; HT_HG-U133A

CFLAR IGF2BP2 MAP4 RANBP3 SIPA1L3 AHCYL2

1.73e-041989463434_DN
DrugMetronidazole [443-48-1]; Down 200; 23.4uM; MCF7; HT_HG-U133A

ST20 MAP4 RANBP3 ITSN1 PVR CNGB3

1.73e-041989461503_DN
DrugMaprotiline hydrochloride [10347-81-6]; Up 200; 12.8uM; HL60; HG-U133A

CFLAR ATG13 ITSN1 RDX VAMP4 TGM5

1.73e-041989461621_UP
Drug5186324; Down 200; 2uM; MCF7; HT_HG-U133A_EA

ST20 MAP4 RANBP3 AHCYL2 MAPK7 F8

1.78e-04199946900_DN
DrugThiethylperazine malate [52239-63-1]; Down 200; 6uM; HL60; HT_HG-U133A

GTF2A1 RAB33A MAP4 ITSN1 PVR ADGRE1

1.78e-041999466154_DN
DrugXylometazoline hydrochloride [1218-35-5]; Down 200; 14.2uM; MCF7; HT_HG-U133A

MED20 GTF2A1 MAP4 FBXO28 SIPA1L3 PVR

1.78e-041999467020_DN
DrugLysergol [602-85-7]; Down 200; 15.8uM; HL60; HT_HG-U133A

MAP4 DYNC2H1 RANBP3 LY9 VAMP4 F8

1.78e-041999461325_DN
DrugEserine sulfate, physostigmine sulfate [64-47-1]; Down 200; 6.2uM; HL60; HG-U133A

CFLAR TTBK2 RDX NCL AHCYL2 NNT

1.78e-041999461776_DN
Drug5-aza-2′-deoxycytidine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

GTF2A1 DYNC2H1 SIPA1L3 PVR AHCYL2 VAMP4

1.78e-04199946920_DN
DiseaseDegenerative polyarthritis

EZR MYH13 SGCG MSN

2.36e-0493954C0029408
DiseaseOsteoarthrosis Deformans

EZR MYH13 SGCG MSN

2.36e-0493954C0086743
Diseasesmoking status measurement, forced expiratory volume

PSG9 RDX

5.54e-0411952EFO_0004314, EFO_0006527
Diseasepeak insulin response measurement

BLVRA IGF2BP2

7.82e-0413952EFO_0008000
DiseaseDEAFNESS, AUTOSOMAL RECESSIVE (disorder)

PNPT1 EPS8

7.82e-0413952C1846647
Diseaseperiodontitis

IGF2BP2 ST20 MYH13 NFASC ADGRE1

7.86e-04223955EFO_0000649
Diseasecongenital heart disease (implicated_via_orthology)

USP17L1 USP17L3 CHD8

1.45e-0369953DOID:1682 (implicated_via_orthology)
Diseasepsoriasis, type 2 diabetes mellitus

IGF2BP2 RDX CCDC88B

1.85e-0375953EFO_0000676, MONDO_0005148
Diseaseblood rubidium measurement

NCKAP5 TEK

3.17e-0326952EFO_0021529

Protein segments in the cluster

PeptideGeneStartEntry
VKQQDPLVYKAIQQG

ACSBG2

596

Q5FVE4
VRKVGAFVNKPINQV

ATG13

371

O75143
SPTVEENNVVVKKQG

GRAMD1C

31

Q8IYS0
QAKNAQGQPAKVVTI

CHD8

326

Q9HCK8
QGQPAKVVTIQLQVQ

CHD8

331

Q9HCK8
QKPQQKSEGALEVQV

CCDC88B

696

A6NC98
FPSIQVTGNKILVKQ

CD28

11

P10747
FLGKNVQDIKNVVLQ

FLOT2

91

Q14254
TEQGPQIDQKQFDKI

ALDH1A3

351

P47895
DQTVNPQNGFVRNKV

DDX20

621

Q9UHI6
QEQIKKQKANIFVPS

CC2D2B

161

Q6DHV5
QLGAQQEPVKKSIQE

CFLAR

216

O15519
QVIQKPGVVQRFVKF

KPNA5

121

O15131
KKDPATQQAFVFGQN

RANBP3

251

Q9H6Z4
QQGKVQKLEFPQEAN

RAB33A

216

Q14088
PNEVKVNQKQTVVAV

RGS9

211

O75916
QPNTTGKQLFDQVVK

RDX

21

P35241
LTGQQVAIKKIPNAF

MAPK7

76

Q13164
KNKFIAAQGPKQETV

PTPRE

201

P23469
PQNFKLSQDDIKGIQ

MMP7

241

P09237
GNVQIQNKKVDISKV

MAP4

1021

P27816
VFQKEEIEPLQGKQQ

DST

5326

Q03001
TFSKKENNQVPAVVA

NID1

206

P14543
PQNHEFKQAIGIKVN

FAM151B

261

Q6UXP7
QPNTTGKQLFDQVVK

MSN

21

P26038
AQSGSVPQFKKVVFQ

F8

1741

P00451
QVKQQEQKYPQGVAS

IGF2BP2

581

Q9Y6M1
KQQQKAAFPSEGVVV

LIX1

41

Q8N485
FEKATFIKVPQNQNG

NCL

506

P19338
KIKKVNVQVSFNPEN

PARP14

696

Q460N5
NVQVSFNPENKQKGI

PARP14

701

Q460N5
KVGKQIVENFSPNQT

NFASC

976

O94856
GKNESNIKPVQTVNI

BRCA1

911

P38398
IPAKIQQVANIAQKF

DYNC2H1

596

Q8NCM8
QQQGKKPTAEQELYI

EFCAB5

526

A4FU69
LSNFGAVPQQKKLQE

E2F6

131

O75461
QAVSKQQVFSVQKGL

CCNF

291

P41002
GPQVQLVNNSFKGIK

DPP9

646

Q86TI2
GPQVQLVNNRFKGVK

DPP8

671

Q6V1X1
FNKGQIINVLNKEDP

ITSN1

1176

Q15811
VTKLQQQVKTNGAGV

FBXO28

261

Q9NVF7
DFSPVVQQQKGKTIK

BPIFB6

221

Q8NFQ5
VPNVGVNKNIFLKDQ

BLVRA

241

P53004
GPKQIQVAEAQNVLK

DNAH14

2466

Q0VDD8
VFNLQGKTPVSQKEE

LY9

606

Q9HBG7
KVSENEGFIPVNKNL

HGSNAT

551

Q68CP4
KQESGVKIITQQVQP

EMSY

451

Q7Z589
QKKFHVPRQNVPVIN

EPS8

706

Q12929
QPNTTGKQLFDQVVK

EZR

21

P15311
NNAGIPQDLKTKVNV

FLRT1

66

Q9NZU1
VGFAQQTLKPQNRKV

GPX6

16

P59796
AKLVSGVFKPNQQTV

POLI

231

Q9UNA4
GTKVQFNLQFTKPNA

SASS6

556

Q6UVJ0
DQQVFIQKVVPITNK

KCTD3

496

Q9Y597
KNQVTQLKEQVPGFT

MTHFD1

21

P11586
LFNKIRKQQQVPVAG

MED20

196

Q9H944
QLTVGVPKEIFQNEK

NNT

56

Q13423
QGLVKQLVGKNFNVV

PDILT

386

Q8N807
VLAKPQNTAEVQKVQ

PVR

141

P15151
EFQQSFGKPTKQEIN

RTL4

131

Q6ZR62
PRTVKKQIQFADQKQ

AHCYL2

116

Q96HN2
FGPRNDKIKHVQNQV

VAMP4

46

O75379
KNLISAFQKPDQGIV

SH2D1A

81

O60880
NTVKGKVPLQFSGQN

TLL1

126

O43897
KVPLQFSGQNEKNRV

TLL1

131

O43897
EQPQPVQRQFTNKEK

TMEM200C

586

A6NKL6
QENVEKGQVQTKPTS

NCKAP5

1481

O14513
KFQQSGQKLFIPQIT

PSG9

371

Q00887
KKQVDTNTKNVFGQP

SIPA1L3

1476

O60292
QNPFSIQVIRKSNGK

SI

196

P14410
NPFQIVLVKGNKLNT

PIK3CB

331

P42338
KVGVKYTQQIIQGIQ

PNPT1

246

Q8TCS8
LKVGPKMVEVQNQQF

SGCG

126

Q13326
KQIQQCQEGTAVKPA

ADGRE1

331

Q14246
TKVNKVKPIGENNEN

CNGB3

6

Q9NQW8
VFPVQNINLVTQKKA

CYSLTR1

126

Q9Y271
LHIFQPKGKINNQVE

ZNF525

151

Q8N782
IQPQQILFTGNKTQV

GTF2A1

221

P52655
QEQNKTKPEFNVGKV

USP17L3

441

A6NCW0
AIEKQLQQGIFPIKN

ZNF804B

141

A4D1E1
QFPQLKKVIQFVCGN

SMC1B

601

Q8NDV3
VSQVQENGFVKKLEP

ST20

11

Q9HBF5
KEQQSNIAVFQGKKI

SRFBP1

411

Q8NEF9
NVALKVESAQQPKQV

TTBK2

46

Q6IQ55
VKVGNEYVTKGQNVQ

MYH13

406

Q9UKX3
QEQNKTKPEFNVGKV

USP17L1

441

Q7RTZ2
RSVQKSDQQNIKVPG

TEK

581

Q02763
QQKVFLGVLKPQHQA

TGM5

666

O43548
DNIKYQPKGGQVQIV

MAP2

1681

P11137
NNQDFIPFTKKRVGV

ZC2HC1C

121

Q53FD0
NQKTVPNIFVNKVHV

TXNRD3

116

Q86VQ6
QGTLQEKPIQINYKQ

SPZ1

346

Q9BXG8
VVEQNGSFQVKIPKN

ZNF740

86

Q8NDX6
QEVGGQTAVKNQAKV

XIRP1

1601

Q702N8
PVKNGKQFTKQNGET

HIVEP1

101

P15822
VGIDSFQPSVQKQLK

ZNF518B

416

Q9C0D4
QQKVPTIQQVHKFDI

ZNF527

181

Q8NB42
VCVKFIQGNQKNGSV

MYO1B

1106

O43795
KKENIVNVVQGSLQF

MYO1H

981

Q8N1T3